AR013087A1 - FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT - Google Patents

FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT

Info

Publication number
AR013087A1
AR013087A1 ARP980102753A AR013087A1 AR 013087 A1 AR013087 A1 AR 013087A1 AR P980102753 A ARP980102753 A AR P980102753A AR 013087 A1 AR013087 A1 AR 013087A1
Authority
AR
Argentina
Prior art keywords
amprenavir
understand
prepare
pharmaceutical compositions
antiviral compound
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR013087A1 publication Critical patent/AR013087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forma V cristalina del compuesto de formula (I), util como composicion farmacéutica en el tratamiento de infeccion retrovirus y con actividad comoinhibidor HIV proteasa. La forma V puede ser producida por cristalizacion desde una solucion acuosaCrystalline form V of the compound of formula (I), useful as a pharmaceutical composition in the treatment of retrovirus infection and with activity as an HIV protease inhibitor. Form V can be produced by crystallization from an aqueous solution

ARP980102753 1997-06-13 1998-06-10 FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT AR013087A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712253.5A GB9712253D0 (en) 1997-06-13 1997-06-13 Antiviral compound

Publications (1)

Publication Number Publication Date
AR013087A1 true AR013087A1 (en) 2000-12-13

Family

ID=10814058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102753 AR013087A1 (en) 1997-06-13 1998-06-10 FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT

Country Status (6)

Country Link
AR (1) AR013087A1 (en)
AU (1) AU8437898A (en)
CO (1) CO4940473A1 (en)
GB (1) GB9712253D0 (en)
HR (1) HRP980321A2 (en)
WO (1) WO1998056781A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (en) 1992-08-25 1999-01-01 Searle & Co HYDROXYETHYLAMINE-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS.
AU2001259817A1 (en) * 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
DK2767539T3 (en) 2002-05-16 2017-09-11 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
JPH0971575A (en) * 1995-09-07 1997-03-18 Kissei Pharmaceut Co Ltd New crystalline sulfonamide compound

Also Published As

Publication number Publication date
AU8437898A (en) 1998-12-30
GB9712253D0 (en) 1997-08-13
CO4940473A1 (en) 2000-07-24
HRP980321A2 (en) 1999-04-30
WO1998056781A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
EA200801144A1 (en) POLYCYCLIC CARBAMOYLPYRIDON DERIVATIVE, HAS INHIBITOR ACTIVITY WITH RESPECT TO HIV INTEGRASES
MX9307821A (en) NEW KIND OF PROTEASE ASPARTILE INHIBITORS.
ES2174992T3 (en) INTERMEDIATE PRODUCTS FOR THE OBTAINING OF INHIBITING COMPOUNDS OF RETROVIRAL PROTEASES.
MX9403380A (en) HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
MXPA04006553A (en) 4-oxoquinoline compound and its use as hiv integrase inhibitor.
AR031520A1 (en) AN INHIBITOR COMPOSITE OF ASPARTILO PROTEASA, A COMPOSITION THAT INCLUDES IT AND A METHOD TO TREAT A PATIENT WITH SUCH COMPOSITION
CL2004002061A1 (en) COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES CONTAINING NITROGEN; PHARMACEUTICAL COMPOSITION; AND ITS USE AS AN ANTIVIRAL AGENT, INTEGRASA INHUBIDATOR AND AS AN ANTI-HIV AGENT.
IS2714B (en) Cell accumulation of phosphomate analogues on HIV protease inhibitory compounds
UY26962A1 (en) CRYSTALLINE MONOHIDRATE, PROCEDURE FOR PREPARATION AND USE FOR PREPARATION OF A MEDICINAL PRODUCT
ES2191977T3 (en) SOLUTIONS AND DISPERSIONS IN SOLID STATE OF PHARMACOS LITTLE SOLUBLES IN WATER.
PE20090605A1 (en) COMPOSITIONS OF AMMONIA PHENYLALANINE-LIASA PROCARIOTICA AND METHODS OF TREATMENT OF CANCER USING COMPOSITIONS OF THE SAME
AR051778A2 (en) DERIVATIVES OF DIMETHYLAMINOCROTONIC ACID AND PROCESSES FOR SUPREPARATION
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
CU23366B7 (en) SUBSTITUTED OXAZOLIDINONES FOR COMBINATION THERAPY
ES2192201T3 (en) PIRANONA COMPOUNDS USEFUL FOR THE TREATMENT OF RETROVIRAL INFECTIONS.
ES2177868T3 (en) HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES.
AR052034A1 (en) POTASSIC SALT OF AN HIV INTEGRAS INHIBITOR
AR030021A1 (en) COMPOSITE OF A REPLACED PYRIMIDINONES, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF USEFUL MEDICINES FOR THE SELECTIVE INHIBITION OF THE COAGULATION CASCADE
ATE485261T1 (en) SALICYLIC ACID DERIVATIVES
AR034120A1 (en) HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-4,5, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT OR MODULATE NITRIC ACID SYNTHESIS
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
ES2101252T3 (en) HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
MX9206563A (en) USE OF AMPHOTERICIN B DERIVATIVES AS PROTEASE INHIBITORS.
AR013087A1 (en) FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT